Key words
benzimidazole carboxaldehydes - dimethyl acetal - C–C bond cleavage - task-specific
ionic liquid
In drug discovery programs and for identifying biological leads, nitrogen-containing
fused heterocyclic molecules play an important role as molecular templates. Among
them, benzimidazole-containing heterocycles are of importance because of their broad
spectrum of biological and therapeutic potentialities,[1] making them one of the more widely investigated heterocyclic scaffolds. In addition
to their biological potential, they are important intermediates in many synthetic
organic and inorganic reactions,[2] in dye and polymer synthesis,[3] in fluorescence,[4] chemosensing,[5] crystal engineering,[6] and corrosion science.[7] They also act as ligands in the synthesis of transition-metal complexes of structural
and biological interest.[8] Therefore, their synthesis has received considerable attention and this has led
to the development of several methods for the synthesis of benzimidazoles. These include
the condensation of aromatic 1,2-diamines with carboxylic acids or their derivatives,
generally under harsh conditions,[3]
[9] oxidative cyclocondensation[10] with aldehydes, or copper(I) catalysed coupling of o-haloacetanilides with amines or amidines,[11] while very recently we and others also developed a benzimidazole synthesis by reaction
with 1,2-diaminobenzene derivatives with active methylene compounds using a range
of activators.[12]
[13]
[14] In addition to these methods, rearrangement of quinoxalines or quinoxalone derivatives
under different conditions to form benzimidazole derivatives have been documented.[14] Derivatives of benzimidazole-2-carboxaldehyde have found applications in diverse
therapeutic areas,[15] as well as in chalcone preparation,[16] generation of Schiff’s bases,[17] and for the creation of a library of fused polyheterocycles.[18] Unfortunately no straightforward synthesis of functionalized benzimidazole-2-carboxaldehydes
has been reported to date. They can be synthesized via multistep pathways (such as
pathways 1–5 in Scheme [1]): (1) condensation of o-phenylenediamine with tartaric acid followed by cleavage of the diol with NaIO4;[18d]
[e] (2) condensation of 1,2-diaminobenzene with glycolic acid and then oxidation with
MnO2;[19] (3) oxidation of 2-methyl benzimidazole with SeO2;[20] (4) direct and/or directed lithiation at the 2-position of benzimidazole followed
by trapping with DMF;[21] and (5) condensation of 1,2-diamino enzene with ethyl diethyoxyacetate in Na/EtOH
followed by hydrolytic cleavage.[22]
Scheme 1 General strategies involved in the synthesis of benzimidazole 2-carboxaldehydes
However, despite some notable advantages of the reported methods for the synthesis
of benzimidazoles and benzimidazole 2-carboxaldehydes they generally suffer from a
range of drawbacks, such as the requirement for stoichiometric or excess amounts of
strong oxidants, high temperatures, transition-metal catalysts or harsh reaction conditions.
In the area of organic synthesis, C–C bond-cleavage reaction is a topic of interest
that allows C-C/C-N bond annulation to be used to construct new molecules of interest.[23] In spite of significant advances in this field, most methods rely on transition-metal
catalysis. In recent times, much attention has been focused on organic reactions promoted
by ionic liquids.
As a part of our ongoing program to explore the potential of protic ionic liquids
in the activation of various functional groups and subsequent organic transformations,
we have already demonstrated their efficacy as bifunctional catalysts for Boc protection-deprotection
of amines, cleavage of 1,3-dioxolanes and in grinding chemistry.[10a]
[24] Herein, we wish to report a strategy for the direct synthesis of dimethyl acetal
protected benzimidazole 2-carboxaldehydes using methyl 4,4-dimethoxy-3-oxobutanoate
in the presence of 1-butyl imidazolium trifluoroacetate (HBIm·TFA) as a bifunctional
catalyst (Scheme [2]).
Scheme 2 Protic ionic liquid promoted synthesis of benzimidazole 2-carboxaldehyde dimethylacetals
Table 1 Screening of Catalysts for Optimisation of Reaction
|
|
Entry
|
Activator
|
Temp (°C)
|
Time
|
Yield (%)a
|
|
1
|
[BMIm]Brb
|
80
|
4 h
|
50
|
|
2
|
[BMIm]OHb
|
80
|
12 h
|
20
|
|
3
|
[HBIm][TFA]b
|
80
|
15 min
|
95
|
|
4
|
[HBIm][TFA]b
|
rt
|
2 h
|
NR
|
|
5
|
none
|
80
|
2 h
|
NR
|
|
6
|
[Et3NH][TFA]b
|
80
|
2 h
|
trace
|
|
7
|
SiO2-KHSO4
|
80
|
2 h
|
80
|
|
8
|
SiO2-HClO4
|
80
|
2 h
|
80
|
|
9
|
SiO2-H2SO4
|
80
|
3 h
|
82
|
|
10
|
FeCl3-SiO2
|
80
|
90 min
|
87
|
|
11
|
Nano TS 1
|
80
|
50 min
|
83
|
|
12
|
Amberlite IR120H+
|
80
|
2 h
|
78
|
|
13
|
Amberlyst 15
|
80
|
90 min
|
73
|
|
14
|
[HBIm][TFA]
|
80
|
30 min
|
92c
|
a Isolated yield on 1 mmol scale.
b 5 mol% was used.
c 10 mmol scale.
To optimize the reaction conditions, o-phenylenediamine (1a) and methyl 4,4-dimethoxy-3-oxobutanoate (2) were chosen for the model reaction under different reaction conditions. Previously
we have reported[12a] that the neutral ionic liquid [BMIm]Br or basic ionic liquid [BMIm]OH (10 mol%)
could be utilised as activators for the synthesis of benzimidazoles by reaction of
o-phenylenediamines with β-keto esters or amides at 115–120 °C, with the reaction proceeding
through formation of a seven-membered benzodiazepinone intermediate. Unfortunately
our initial attempts with these ionic liquid activators failed to produce the desired
product in satisfactory yield on heating 1a with 2 at 80 °C for 4 or 12 hours, respectively (Table [1], entries 1 and 2), and further increasing the temperature did not improve the yield,
probably due to decomposition of 2. However, heating the reaction mixture at 80 °C in the presence of 5 mol% of protic
ionic liquid (HBIm·TFA) for 15 min produced the desired benzimidazole 2-carboxldehyde
dimethyl acetal 3a in 95% yield (entry 3), although reactions at room temperature or without catalyst
were not successful (entries 4 and 5). The appearance of two singlets at δ = 5.70
ppm (1H) and 3.46 ppm (6H) in the 1H NMR spectrum and at δ = 98.4 and 53.6 ppm in the 13C NMR spectra of 3a corroborated the presence of the dimethyl acetal group (see Supporting Information).
A molecular ion at m/z 193 further supported the structure of 3a. We also carried out the reaction with triethyl ammonium trifluoroacetate ([Et3NH][TFA]), prepared from an equimolar mixture of triethylamine and trifluoroacetic
acid under identical reaction conditions (entry 6) but no product was detected. We
also screened some silica supported acidic reagents such as SiO2-KHSO4 (40 mg, 10% KHSO4),[25] SiO2-HClO4 (40 mg, 10% w/v),[26] SiO2-H2SO4 (40 mg, 10% w/v),[27] SiO2-FeCl3 (32 mg containing ca. 10% FeCl3),[12b]
[28] and nano titania-silica (TS1).[29] These supported reagents also afforded 2-(1,1-dimethoxy)methyl benzimidazole (3a) in 80, 80, 82, 87, and 83% yield, respectively (entries 7–11). The reaction was
also investigated using commercially available sulfonic acid resins Amberlyst-15 and
Amberlite IR 120H+ (entries 12 and 13). The resin-based catalysts resulted in lower yields compared
to the silica supported reagents. No reaction was observed when the model reaction
was conducted using 5 mol% of neat trifluoroacetic acid (results not shown). These
control experiments indicated that both a proton and imidazolium cation are essential
to produce 3a in high yield.
From the results presented in Table [1], the protic ionic liquid (HBImTFA) showed the best catalytic activity for the synthesis
of 3a with respect to both reaction time and yield. The reaction could also be scaled up
to 10 mmol scale with very little decrease of the yield using the same mol% of ionic
liquid (entry 14). It is noteworthy that the high yield of 3a indicates its stability in the mildly acidic reaction medium. Another important feature
of the present protocol is the recyclability of the ionic liquid for five cycles without
significant loss of catalytic efficiency (95–88%). Since most of the benzimidazole
product solidified after completion of reaction, the product could be collected by
filtration and the mother liquor containing the ionic liquid recycled after evaporation
of solvent.
Having optimized the reaction conditions, the scope of the reaction with various o-phenylenediamines with methyl 4,4-dimethoxy-3-oxobutanoate was subsequently explored;
the results are summarized in Figure [1]. A wide range of aromatic diamines with electron-withdrawing or electron-donating
groups at different positions of the aromatic ring, reacted smoothly in the presence
of protic ionic liquid ([HBIm]TFA) to afford benzimidazole-2-carboxaldehyde dimethyl
acetals 3b–e and 3g–l in good to excellent yields within two hours. In contrast, 4-nitro-1,2-diaminobenzene
afforded a different type of benzimidazole by C–C bond cleavage due to the presence
of the strongly electron-withdrawing group in the aromatic ring depleting the negative
charge on the nitrogen in intermediate D (see Scheme [3] below), with methoxy-directed oxidative cleavage resulting in 6-nitro-1H-benzo[d]imidazole-2-yl acetate (3f) in 35% yield with concomitant formation of many other unidentified products. All
the synthesized products 3a–l were characterized by spectroscopic analyses. Unfortunately, 2,3-diaminopyridine
failed to give the corresponding pyrido-imidazole derivative; rather, it produced
the seven-membered heterocycle 3m, as an inseparable mixture of tautomers, in 75% yield. A similar trend was observed
in the case of 2-aminothiophenol, which yielded benzothiazepinone 3n as the sole product. Attempted reaction of 2-aminophenol yielded a mixture of unidentified
products, probably due to the lower nucleophilicity of the phenolic OH group, meaning
that the cyclisation step is not favourable.
Figure 1
o-Phenylenediamine scope
Considering the mechanism of the reaction, we anticipated that both the imidazolium
cation and N-H proton are indispensable for catalytic activity as neither the imidazolium
cation (entries 1 and 2) nor proton alone (entries 6, 12 and 13) provide the optimum
yield of product, but N-butyl imidazolium trifluoroacetate provided the best yield in the shortest reaction
time. Thus, we speculate that dual activation of the ketone oxygen of the ketone and
the oxygens of the acetal group of reagent 2 (A in Scheme [3]) by both the proton and imidazolium cation activates the ketone carbonyl, thereby
making it more susceptible to nucleophilic attack by the amino group of the o-phenylenediamine.
Scheme 3 Plausible mechanism for dual activation of 2 by [HBIm]TFA and catalytic cycle in the synthesis of acetal 3
The resulting imine C undergoes ring-closure onto the second amino group to form aminal D followed by hydrogen-bond-assisted C–C bond cleavage to give the benzimidazole (Scheme
[3]). Although the possibility of simultaneous activation of both carbonyls of 2, leading to B, cannot be overlooked; in such a situation, the benzodiazepinone may result from
attack by the two amino groups on both activated carbonyls.
1H and 13C NMR spectra were recorded with a Bruker Ascend 400 spectrometer (400 MHz for 1H and 100 MHz for 13C). Chemical shifts are reported in parts per million with tetramethylsilane internal
reference, and coupling constants are reported in Hertz. Proton multiplicities are
represented as s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet),
and m (multiplet). Infrared spectra were recorded with a Fourier transform infrared
(FT-IR, Model: Spectrum 100) spectrophotometer as KBr pellets or in thin films. The
reported melting points are uncorrected. High-resolution mass spectrometric (HR-MS)
data were acquired by electrospray ionization with a Q-ToF-micro quadrupole mass spectrometer.
All commercial reagents were used without further purification, unless otherwise specified.
Ethyl acetate and petroleum ether (60−80 °C) were distilled before use. Column chromatography
was performed on silica gel (60−120 mesh, 0.12−0.25 mm). Analytical thin-layer chromatography
was performed on 0.25 mm silica gel plates with a UV254 fluorescent indicator.
General Procedure
The requisite o-phenylenediamine (108 mg, 1 mmol) and methyl 4,4-dimethoxy-3-oxobutanoate (194 mg,
1.1 mmol) were taken in a cone-shaped (10 mL) flask equipped with a small magnetic
bar. HBIm·TFA (12 mg, 0.05 mmol) was then added to the mixture, which was heated at
80 °C without solvent until the disappearance of the o-phenylenediamine (TLC). After completion of reaction, the solid mass was washed several
times with water to remove the ionic liquid catalyst. Finally, the product was purified
by crystallization using ethyl acetate–hexane, and ionic liquid was recovered from
the mother liquor. In some cases, the product was purified by column chromatography
over silica gel, eluting with 10–50% ethyl acetate in hexane.
2-(Dimethoxymethyl)-1H-benzimidazole (3a)
2-(Dimethoxymethyl)-1H-benzimidazole (3a)
Yield: 182 mg (95%); colourless solid; mp 180 °C.
IR (neat): 2824, 1423, 1329, 1116, 1066 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.66–7.64 (dd, J = 5.6, 3.2 Hz, 2 H), 7.30–7.28 (dd, J = 6.0, 3.2 Hz, 2 H), 5.70 (s, 1 H), 3.46 (s, 6 H).
13C NMR (100 MHz, CDCl3): δ = 150.3, 137.9, 122.9, 115.6, 98.4, 53.6.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C10H12N2O2: 193.0977; found: 193.0959.
2-(Dimethoxymethyl)-6-methyl-1H-benzimidazole (3b)
2-(Dimethoxymethyl)-6-methyl-1H-benzimidazole (3b)
Yield: 187 mg (91%); thick liquid.
IR (neat): 2927, 2828, 1692, 1442, 1325, 1107, 1055 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.53 (d, J = 8 Hz, 1 H), 7.40 (s, 1 H), 7.10 (d, J = 7.6 Hz, 1 H), 5.67 (s, 1 H), 3.44 (s, 6 H), 2.47 (s, 3 H).
13C NMR (100 MHz, CDCl3): δ = 150.0, 132.8, 124.4, 115.2, 98.5, 53.5, 21.6.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C11H14N2O2: 207.1134; found: 207.1011.
2-(Dimethoxymethyl)-5,6-dimethyl-1H-benzimidazole (3c)
2-(Dimethoxymethyl)-5,6-dimethyl-1H-benzimidazole (3c)
Yield: 209 mg (95%); colourless solid; mp 100 °C.
IR (neat): 2926, 1691, 1516, 1449, 1192, 1062 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.39 (s, 2 H), 5.66 (s, 1 H), 3.43 (s, 6 H), 2.36 (s, 6 H).
13C NMR (100 MHz, CDCl3): δ = 149.4, 131.9, 115.7, 98.6, 77.0, 53.5, 20.3.
HRMS (ESI-TOF): m/z [M+H]+ calcd for C12H16N2O2: 221.1290; found: 221.1250.
6-Chloro-2-(dimethoxymethyl)-1H-benzimidazole (3d)
6-Chloro-2-(dimethoxymethyl)-1H-benzimidazole (3d)
Yield: 203 mg (90%); colourless solid; mp 140 °C.
IR (neat): 2920, 1421, 1321, 1105, 1055 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.63 (s, 1 H), 7.55 (s, 1 H), 7.25 (s, 1 H), 5.66 (s, 1 H), 3.46 (s, 6 H).
13C NMR (100 MHz, CDCl3): δ = 151.3, 128.6, 123.6, 98.3, 77.0, 53.7.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C10H11ClN2O2: 227.0587; found: 227.0561.
2-(Dimethoxymethyl)-1H-benzimidazole-5-carboxylic Acid (3e)
2-(Dimethoxymethyl)-1H-benzimidazole-5-carboxylic Acid (3e)
Yield: 200 mg (85%); yellowish solid; mp 70 °C.
IR (neat): 2938, 2835, 1679, 1417, 1191, 1055 cm–1.
1H NMR (400 MHz, DMSO-d
6): δ = 12.87 (s, 1 H), 12.74 (s, 1 H), 8.21 (s, 0.5 H), 8.08 (s, 0.5 H), 7.82 (s,
1 H), 7.67 (s, 0.5 H), 7.52 (s, 0.5 H), 5.65 (s, 1 H), 3.38 (s, 6 H).
13C NMR (100 MHz, DMSO-d
6): δ (two tautomers) = 168.2, 153.8, 152.9, 146.4, 142.7, 137.6, 133.9, 125.4, 124.7,
124.4, 123.1, 121.5, 119.2, 114.1, 112.0, 98.9, 55.1, 53.9.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C11H12N2O4: 237.0875; found: 237.0838.
Methyl 2-(6-Nitro-1H-benzo[d]imidazole-2-yl)acetate (3f)
Methyl 2-(6-Nitro-1H-benzo[d]imidazole-2-yl)acetate (3f)
Yield: 83 mg (35%); orange solid; mp 130 °C.
IR (neat): 2944, 1726, 1520, 1339, 1223, 1012 cm–1.
1H NMR (400 MHz, DMSO-d
6): δ = 13.09 (bs, 1 H), 8.45 (s, 1 H), 8.10 (bs, 1 H), 7.71 (bs, 1 H), 4.11 (s, 2
H), 3.70 (s, 3 H).
13C NMR (100 MHz, DMSO-d
6): δ = 169.2, 152.8, 142.9, 139.6, 118.4, 115.1, 112.2, 108.6, 52.7, 35.5.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C10H9N3O4: 236.0671; found: 236.0830.
1-Benzyl-2-(dimethoxymethyl)-1H-benzimidazole (3g)
1-Benzyl-2-(dimethoxymethyl)-1H-benzimidazole (3g)
Yield: 231 mg (82%); thick liquid.
IR (neat): 2938, 2832, 1607, 1457, 1334, 1198, 1062 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.83 (d, J = 7.6 Hz, 1 H), 7.31–7.15 (m, 6 H), 7.14 (d, J = 6.4 Hz, 2 H), 5.58 (s, 3 H), 3.45 (s, 6 H).
13C NMR (100 MHz, CDCl3): δ = 149.6, 141.9, 136.3, 135.7, 128.5, 127.4, 126.5, 123.3, 122.2, 120.3, 110.4,
100.6, 54.6, 47.6.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C17H18N2O2: 283.1447; found: 283.1429.
1-Butyl-2-(dimethoxymethyl)-1H-benzimidazole (3h)
1-Butyl-2-(dimethoxymethyl)-1H-benzimidazole (3h)
Yield: 198 mg (80%); thick liquid.
IR (neat): 2956, 1462, 1421, 1334, 1203, 1063 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.79 (d, J = 7.2 Hz, 1 H), 7.39 (d, J = 7.2 Hz, 1 H), 7.32–7.24 (m, 2 H), 5.60 (s, 1 H), 4.30 (t, J = 8 Hz, 2 H), 3.47 (s, 6 H), 1.86–1.79 (m, 2 H), 1.47–1.38 (m, 2 H), 0.98 (t, J = 7.2 Hz, 3 H).
13C NMR (100 MHz, CDCl3): δ = 149.2, 141.9, 135.6, 123.1, 122.1, 120.3, 110.0, 100.5, 54.7, 44.1, 31.7, 20.2,
13.8.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C14H20N2O2: 249.1603; found: 249.1589.
1-Hexyl-2-(dimethoxymethyl)-1H-benzimidazole (3i)
1-Hexyl-2-(dimethoxymethyl)-1H-benzimidazole (3i)
Yield: 246 mg (89%); yellowish sticky solid.
IR (neat): 2929, 1462, 1421, 1334, 1203, 1063 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.79 (dd, J = 11.6, 2.0 Hz, 1 H), 7.39 (dd, J = 5.7, 2.0 Hz, 1 H), 7.32–7.24 (m, 2 H), 5.59 (s, 1 H), 4.30 (t, J = 7.6 Hz, 2 H), 3.48 (s, 3 H), 1.88–1.80 (m, 2 H), 1.41–1.32 (m, 6 H), 0.90 (t, J = 7.2 Hz, 3 H).
13C NMR (100 MHz, DMSO-d
6): δ = 149.2, 142.0, 135.6, 123.1, 122.1, 120.4, 110.0, 100.7, 54.7, 44.3, 31.4, 29.6,
22.5, 14.0.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C16H24N2O2: 277.1916; found: 277.1789.
1-Octyl-2-(dimethoxymethyl)-1H-benzimidazole (3j)
1-Octyl-2-(dimethoxymethyl)-1H-benzimidazole (3j)
Yield: 275 mg (90%); yellowish sticky solid.
IR (neat): 2925, 1461, 1336, 1201, 1066, 965 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.80 (t, J = 6.8 Hz, 1 H), 7.40 (d, J = 7.2 Hz, 1 H), 7.33–7.26 (m, 2 H), 5.60 (s, 1 H), 4.31 (t, J = 7.6 Hz, 2 H), 3.49 (s, 3 H), 1.87–1.81 (m, 2 H), 1.38–1.29 (m, 10 H), 0.90 (t,
J = 7.2 Hz, 3 H).
13C NMR (100 MHz, DMSO-d
6): δ = 149.2, 142.0, 135.7, 123.1, 122.1, 120.4, 110.0, 100.7, 54.7, 44.4, 31.8, 29.7,
29.2, 29.1, 27.0, 22.6, 14.1.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C18H28N2O2: 305.2229; found: 305.2210.
1-Allyl-2-(dimethoxymethyl)-1H-benzimidazole (3k)
1-Allyl-2-(dimethoxymethyl)-1H-benzimidazole (3k)
Yield: 200 mg (86%); thick liquid.
IR (neat): 2933, 2831, 1620, 1515, 1331, 1206, 1064 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.80–7.78 (m, 1 H), 7.36–7.24 (m, 3 H), 6.00–5.90 (m, 1 H), 5.57 (s, 1 H),
5.20 (d, J = 10 Hz, 1 H), 5.10 (d, J = 17.2 Hz, 1 H), 4.96 (d, J = 5.6 Hz, 2 H), 3.46 (s, 6 H).
13C NMR (100 MHz, CDCl3): δ = 149.2, 142.0, 135.6, 132.4, 123.3, 122.2, 120.3, 117.3, 110.3, 100.7, 54.8,
46.6.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C13H16N2O2: 233.1290; found: 233.1302.
2-(Dimethoxymethyl)-1-(prop-2-ynyl)-1H-benzimidazole (3l)
2-(Dimethoxymethyl)-1-(prop-2-ynyl)-1H-benzimidazole (3l)
Yield: 212 mg (92%); thick liquid.
IR (neat): 2933, 2821, 2311, 1694, 1516, 1461, 1336, 1067 cm–1.
1H NMR (400 MHz, CDCl3): δ = 7.80 (d, J = 7.6 Hz, 1 H), 7.55 (d, J = 8 Hz, 1 H), 7.39–7.28 (m, 2 H), 5.61 (s, 1 H), 5.16 (s, 2 H), 3.50 (s, 6 H).
13C NMR (100 MHz, CDCl3): δ = 148.8, 141.8, 135.1, 123.7, 122.7, 120.4, 110.1, 100.8, 77.1, 73.1, 55.0, 33.7.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C13H14N2O2: 231.1134; found: 231.1045.
(Z)-2-(Dimethoxymethyl)-1H-pyrido[2,3-b][1,4]diazepin-4(5H)-one and (Z)-4--(Dimethoxymethyl)-1H-pyrido[3,2-b][1,4]diazepin-2(5H)-one (3m)
(Z)-2-(Dimethoxymethyl)-1H-pyrido[2,3-b][1,4]diazepin-4(5H)-one and (Z)-4--(Dimethoxymethyl)-1H-pyrido[3,2-b][1,4]diazepin-2(5H)-one (3m)
Yield: 176 mg (75%); yellowish solid; mp 140 °C.
IR (neat): 3118, 2932, 1669, 1619, 1460, 1103, 1044 cm–1.
1H NMR (400 MHz, DMSO-d
6): δ = 8.26–8.24 (dd, J = 6.8, 1.2 Hz, 1 H), 7.15 (t, J = 7.2 Hz, 1 H), 7.01–6.99 (dd, J = 7.6, 1.2 Hz, 1 H), 6.35 (s, 1 H), 6.18 (s, 2 H), 5.20 (s, 1 H), 3.34 (s, 6 H).
13C NMR (100 MHz, DMSO-d
6): δ = 160.0, 158.0, 142.9, 142.5, 117.9, 113.8, 111.8, 103.1, 99.8, 53.9.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C11H37N3O3: 236.1035; found: 236.1023.
(Z)-2-(Dimethoxymethyl)benzo[b][1,4]thiazepin-4(5H)-one (3n)
(Z)-2-(Dimethoxymethyl)benzo[b][1,4]thiazepin-4(5H)-one (3n)
Yield: 70%; thick liquid.
IR (neat): 3276, 2945, 1615, 1478, 1438, 1272, 1150, 1066 cm–1.
1H NMR (400 MHz, CDCl3): δ = 10.56 (s, 1 H), 7.28 (m, 2 H), 6.95 (t, J = 7.6 Hz, 2 H), 4.88 (s, 1 H), 4.81 (s, 1 H), 3.74 (s, 3 H), 3.42 (s, 3 H).
13C NMR (100 MHz, CDCl3): δ = 170.8, 148.1, 135.4, 129.0, 127.3, 122.7, 117.3, 115.9, 84.9, 79.8, 55.8, 50.9.
HRMS (ESI-TOF): m/z [M + H]+ calcd for C12H13NO3S: 252.0649; found: 252.1009.
